A detailed history of Susquehanna Fundamental Investments, LLC transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna Fundamental Investments, LLC holds 286,408 shares of ALLO stock, worth $607,184. This represents 0.06% of its overall portfolio holdings.

Number of Shares
286,408
Holding current value
$607,184
% of portfolio
0.06%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

BUY
$2.92 - $5.63 $836,311 - $1.61 Million
286,408 New
286,408 $1.28 Billion
Q3 2023

Nov 14, 2023

SELL
$3.17 - $5.96 $106,626 - $200,470
-33,636 Reduced 17.22%
161,673 $512,000
Q4 2022

Feb 14, 2023

BUY
$5.62 - $11.11 $1.1 Million - $2.17 Million
195,309 New
195,309 $1.23 Million
Q2 2021

Aug 11, 2021

SELL
$23.49 - $35.8 $696,642 - $1.06 Million
-29,657 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$25.79 - $39.02 $764,854 - $1.16 Million
29,657 New
29,657 $1.05 Million

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $305M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Susquehanna Fundamental Investments, LLC Portfolio

Follow Susquehanna Fundamental Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.